4D Molecular Therapeutics (NASDAQ:FDMT) Given Buy Rating at Chardan Capital

Key Points

• 4D Molecular Therapeutics (NASDAQ:FDMT) has been given a "buy" rating by Chardan Capital, with a target price of $25.00, indicating a potential upside of 455.56% from its current price.
• Several analysts have recently revised their price targets downward, with Barclays and Goldman Sachs setting new targets of $38.00 and $44.00, respectively.
• The company's earnings miss with reported EPS of ($0.86), falling short of the consensus estimate of ($0.84).

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report)'s stock had its "buy" rating restated by research analysts at Chardan Capital in a report released on Friday,Benzinga reports. They currently have a $25.00 target price on the stock. Chardan Capital's price objective would indicate a potential upside of 455.56% from the company's current price.

Several other analysts also recently commented on the stock. Barclays reduced their price objective on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. The Goldman Sachs Group reduced their price target on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research report on Tuesday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $29.56.

4D Molecular Therapeutics Stock Up 2.0%

FDMT opened at $4.50 on Friday. The stock has a market capitalization of $208.49 million, a price-to-earnings ratio of -1.42 and a beta of 2.81. 4D Molecular Therapeutics has a twelve month low of $2.23 and a twelve month high of $18.14. The company has a 50-day simple moving average of $4.15 and a 200 day simple moving average of $4.04.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 767,126.06% and a negative return on equity of 33.26%. Sell-side analysts anticipate that 4D Molecular Therapeutics will post -2.84 EPS for the current fiscal year.

Institutional Trading of 4D Molecular Therapeutics

A number of hedge funds have recently bought and sold shares of the company. BVF Inc. IL lifted its position in 4D Molecular Therapeutics by 70.8% in the first quarter. BVF Inc. IL now owns 4,561,289 shares of the company's stock valued at $14,733,000 after purchasing an additional 1,890,647 shares during the last quarter. Vanguard Group Inc. raised its holdings in 4D Molecular Therapeutics by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 2,860,508 shares of the company's stock worth $15,933,000 after purchasing an additional 92,791 shares in the last quarter. Millennium Management LLC raised its holdings in 4D Molecular Therapeutics by 15.0% in the first quarter. Millennium Management LLC now owns 1,633,987 shares of the company's stock worth $5,278,000 after purchasing an additional 213,264 shares in the last quarter. Federated Hermes Inc. grew its stake in shares of 4D Molecular Therapeutics by 33,131.8% in the first quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company's stock worth $4,038,000 after acquiring an additional 1,246,419 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of 4D Molecular Therapeutics by 159.5% in the fourth quarter. JPMorgan Chase & Co. now owns 820,069 shares of the company's stock worth $4,568,000 after acquiring an additional 504,086 shares during the last quarter. Institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.